Try to find two reasons to get the COVID vaccine and two reasons not to get the COVID vaccine.
Answers
Answer:
The COVID-19 coronavirus has knocked our world off its axis. We won’t return to anything approaching normal — that is, life without social distancing, quarantines, masks, school closures and other control measures — until most of the world has been vaccinated against the virus. Everyone, therefore, has the same question on their mind: How fast will a vaccine be ready?
The history of vaccine development is not encouraging. “I’ve been working on vaccines for a long time,” says Barney Graham, deputy director of the Vaccine Research Center at the US National Institute of Allergy and Infectious Diseases. “I’ve never seen one take less than about 20 years.” It took 26 years to develop a vaccine for the human papilloma virus, for instance, and 25 years to secure one for rotavirus. And researchers have been trying for more than 50 years to find a vaccine against respiratory syncytial virus, one of the leading causes of infectious disease mortality in infants. Even after Graham’s group figured out a better approach in 2013, the vaccine is still only in the testing phase.
Answer:
The COVID-19 coronavirus has knocked our world off its axis. We won’t return to anything approaching normal — that is, life without social distancing, quarantines, masks, school closures and other control measures — until most of the world has been vaccinated against the virus. Everyone, therefore, has the same question on their mind: How fast will a vaccine be ready?
The history of vaccine development is not encouraging. “I’ve been working on vaccines for a long time,” says Barney Graham, deputy director of the Vaccine Research Center at the US National Institute of Allergy and Infectious Diseases. “I’ve never seen one take less than about 20 years.” It took 26 years to develop a vaccine for the human papilloma virus, for instance, and 25 years to secure one for rotavirus. And researchers have been trying for more than 50 years to find a vaccine against respiratory syncytial virus, one of the leading causes of infectious disease mortality in infants. Even after Graham’s group figured out a better approach in 2013, the vaccine is still only in the testing phase.